Drugs / recombinant human interferon Alpha-1b
recombinant human interferon Alpha-1b
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04320238 | Jan → May 2020 | COVID-19 | Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant human interferon Alpha-1b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04320238 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human interferon Alpha-1b” NCT04320238 ↗ |
| Route | Intranasal | “recombinant human interferon Alpha-1b nasal drops, 2-3 drops for each nostril per time, 4 times per day.” NCT04320238 ↗ |